Biotech startups are usually formed around a drug or biological to hedge the risk of preclinical and early trial work. These are usually developed with some kind of novel process. Usually you get a small early IPO if things work out at that stage to raise working capital. This happens because most traditional VCs won’t fund this type of biotech. That’s changing somewhat. Then the company sells to a major pharma or biotech if the product works out.